http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112409340-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D253-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D253-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
| filingDate | 2020-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112409340-B |
| titleOfInvention | Halogen-substituted phenyl ether compounds and their uses |
| abstract | The invention discloses a halogen-substituted phenyl ether compound and its application. Specifically, the compound represented by formula (I) or its optical isomer, pharmaceutically acceptable salt, prodrug, hydrate or non-aqueous solvate is provided. Experiments have proved that compared with the control compound MGL-3196, the compound represented by the formula (I) obtained by the specific substitution position and the specific substitution type of the present invention has better agonistic activity on THR-β, and has better agonistic activity on THR-β/THR-α. selectivity is significantly improved. In addition, the compounds of the present invention also possess significantly improved pharmacokinetic properties. The application prospect of the compound of the present invention in the preparation of THR-β agonists and medicines for the treatment of applicable indications for THR-β agonists (including dyslipidemia, hypercholesterolemia, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease) excellent. |
| priorityDate | 2019-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.